Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2013

View Archived Issues

Elan profiles PLK-2 inhibitor ELN-582646 for the treatment of Parkinson's disease

Scientists discover novel small-molecule inhibitor of drug-resistant tuberculosis

Uncovering an amygdala-based mechanism and a potential drug target of PTSD

Auspex commences First-HD phase III trial of SD-809 in Huntington's disease

Omni Bio to provide funding for clinical trial of alpha-1-antitrypsin in GVHD

Hisamitsu Pharmaceutical begins phase II study of HP-3060

Vernalis begins phase Ib/II study of V-81444

Daiichi Sankyo reports results from phase III study of antiplatelet agent in Japan

Nymox reports data from pivotal trial of NX-1207

Namisol shows efficacy in treatment of spasticity and pain in MS

RXi Pharmaceuticals reports findings from second phase I study of RXI-109

Lilly reports promising result for LY-2409021 in patients with type 1 and 2 diabetes

Allergan patents novel prostanoid receptor antagonists

Millennium Pharmaceuticals divulges PI3K type 3 inhibitors

Tissue transglutaminase inhibitors emerge from Sanofi R&D

Alios BioPharma patent describes agents for RSV and influenza

CSIR researchers develop agents for tuberculosis

COPD withdrawn from Japanese NDA for fluticasone furoate/vilanterol

Diazepam nasal spray shows safety and bioavailability comparable to marketed rectal gel formulation

Ipsen and Harvard to collaborate on novel engineered botulinum toxins

FDA approves Gilotrif along with companion diagnostic for first-line treatment of metastatic NSCLC

FDA and EMA issue decisions regarding C-Path's trial simulation tool for Alzheimer's disease

Promising first data for AbbVie compound in mild to moderate Alzheimer's disease

PI3Kbeta inhibitors revealed in GlaxoSmithKline patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...